FDA approves new pancreatic cancer drug that extends survival
The FDA has approved a new treatment for metastatic pancreatic cancer after clinical results showed patients lived about twice as long as with standard chemotherapy. The drug offers a meaningful new option for people whose cancer has already progressed after prior treatment.